The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Open accessAbstract
Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psychedelic-assisted therapies currently offer one of the most robust experimental models for eliciting ST, frequently occasioning ego-dissolution and mystical-type experiences that are associated with sustained reductions in depression, anxiety, and addictive behaviors (97, 106).”
From The therapeutic role of self-transcendence in moral injury recovery: theory, mechanisms, and clinical implications (2026) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single-arm pilot study of PAT to treat tobacco use disorder found 67% and 60% of people remained abstinent at 12 and ≥16 months of follow-up [54].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings demonstrate the likely feasibility of conducting such treatment in a substance use disorder [25,54].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [54]
In the citing paper
“In an open-label pilot study, 12 out of 15 treatment-seeking smokers were nicotine abstinent 6 months after two to three administrations of psilocybin (26).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [26]
In the citing paper
“Facilitating the reconnection with their social environment via increased emotional empathy may therefore contribute to clinical efficacy of hallucinogens shown in preliminary studies with addicted patients (24, 26).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738 · cited 1×
“The Fagerström Test for Cigarette Dependence (FTCD; formerly Fagerström Test for Nicotine Dependence) is a 6-item questionnaire widely used to characterize the level of dependence of cigarette smokers (Fagerström, 2012; Heatherton et al., 1991).”
Method(2008) · Medical Entomology and Zoology · Cited by 7,477
The Health consequences of smoking—50 years of progress : a report of the Surgeon General
Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The TLFB is a self-report calendar completed retrospectively by participants indicating the number of cigarettes smoked each day (Sobell and Sobell, 1992).”
BackgroundThe Health Consequences of Smoking -- 50 Years of progress: A Report of the Surgeon General
General, U. S. S. (2014) · PsycEXTRA Dataset · doi:10.1037/e510072014-001 · Cited by 3,368
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800 · cited 1×
“Two measures of recent smoking, exhaled carbon monoxide (CO) and urinary cotinine level (Benowitz et al., 2002), were assessed at intake, weekly throughout the intervention, and at 6-month follow-up.”
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 7×
“This 100- item questionnaire has previously been used to characterize the subjective effects of psilocybin (Griffiths et al., 2006, 2011).”
BackgroundMethodResultInfluentialSelf-citationJorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 3×
“For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”
BackgroundInfluentialGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 3×
“For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”
BackgroundInfluentialCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · cited 1×
“Several plausible mechanisms of hallucinogen-facilitated treatments have been proposed (Bogenschutz and Pommy, 2012; Carhart-Harris et al., 2012, 2014; Ross, 2012; Vollenweider and Kometer, 2010).”
Background
Research works printed but not linked: 4
- Griffiths RR, 1980, Adv Subst Abuse, 1, 1
- Marks DF, 1993, The QUIT FOR LIFE Programme: An easier way to stop smoking and not start again
- National Institute on Drug Abuse, 2005, LSD NIDA Infofacts
- World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: Warning about the dangers of tobacco
Cited by
Sorted by citations
Items 401–500 of 914
Levin, A. W., Nagib, P. B., Deiparine, S., Gao, T. Z., Mitchell, J. J., & Davis, A. K. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103816 · Cited by 21
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
Herrmann, Z. M., Earleywine, M., Leo, J. A. D., Slabaugh, S., Kenny, T., & Rush, A. J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2125467 · Cited by 21
Jensen, M. E., Stenbæk, D. S., Juul, T. S., Fisher, P. M., Ekstrøm, C. T., Knudsen, G. M., & Fink‐Jensen, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066019 · Cited by 25
Jones, G. M., Arias, D., & Nock, M. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-25658-5 · Cited by 23
The psychedelic effects of cannabis: A review of the literature
Wolinsky, D., Barrett, F. S., & Vandrey, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231209194 · Cited by 26
“…depressive disorder (Carhart-Harris et al., 2016a, 2021; Davis et al., 2021; D’Souza et al., 2022; Goodwin et al., 2023), tobacco use disorder (Johnson et al., 2014, 2017), alcohol use disorder (Bogenschutz et al., 2015, 2022; Krebs and Johansen, 2012), obsessive-compulsive disorder (Moreno…”
BackgroundAndrews, C. M., Hall, W., Humphreys, K. N., & Marsden, J. (2024) · Addiction · doi:10.1111/add.16575 · Cited by 21
Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants
Vizeli, P., Studerus, E., Holze, F., Schmid, Y., Dolder, P. C., Ley, L., Straumann, I., Becker, A., Müller, F., Arikci, D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03074-9 · Cited by 25
The philosophy of psychedelic transformation
Letheby, C. (2017) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.4225/55/5900324d2ad60 · Cited by 23
“Small studies have found promising results using LSD and psilocybin to treat addiction (Johnson et al. 2014, Bogenschutz et al. 2015), obsessive-compulsive disorder (Moreno et al. 2006), and anxiety relating to terminal illness (Grob et al. 2011, Gasser et al. 2014).”
ResultJensen, M. E., Stenbæk, D. S., Messell, C., Poulsen, E. D., Varga, T. V., Fisher, P. M., Nielsen, M. K. K., Johansen, S. S., Volkow, N. D., Knudsen, G. M., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251319457 · Cited by 22
“Our findings suggest that rapid reductions in craving and increases in self-efficacy may play a role, consistent with prior studies on psilocybin for addiction treatment (Bogenschutz et al., 2015; Johnson et al., 2014).”
Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114940 · Cited by 20
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 22
Honeychurch, K. C. (2016) · Separations · doi:10.3390/separations3040028 · Cited by 20
Polo-Castellano, C., Álvarez, J. Á., Palma, M., Barbero, G. F., Ayuso, J., & Ferreiro-González, M. (2022) · Journal of Fungi · doi:10.3390/jof8060598 · Cited by 20
Cardiovascular effects and safety of classic psychedelics
Nahlawi, A., Ptaszek, L. M., & Ruskin, J. N. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00608-2 · Cited by 19
Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review
Richard, J., & Garcia‐Romeu, A. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00629-8 · Cited by 22
Self-citationBeyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20thCentury
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1581961 · Cited by 19
“The robust changes in maladaptive behaviors like addiction (Johnson et al. 2014), anxiety (Grob et al. 2011), and depression (Carhart-Harris et al. 2016a) after carefully monitored psychedelic sessions have justified their place in psychiatric research in recent years.”
BackgroundReduced Precision Underwrites Ego Dissolution and Therapeutic Outcomes Under Psychedelics
Stoliker, D., Egan, G. F., & Razi, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.827400 · Cited by 20
“These include addiction, anxiety, and depression (Johnson et al., 2014; Griffiths, 2015; Carhart-Harris et al., 2017, 2021).”
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 22
Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., Roméo, B., & Benyamina, A. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad078 · Cited by 22
Molecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 25
“Administration of moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin was a potentially efficacious adjunct to current smoking cessation treatment and promoted long-term smoking abstinence [159–161].”
BackgroundSolaja, I., Haldane, K., Mason, N. L., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105570 · Cited by 22
5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?
Bryson, A., Carter, O. L., Norman, T. R., & Kanaan, R. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx011 · Cited by 20
“There is strong interest in the therapeutic potential of 5-HT2A agonists in mood disorders and drug addiction (Johnson et al., 2014; Carhart-Harris et al., 2016b; Rucker et al., 2016).”
BackgroundNutt, D. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675754 · Cited by 19
“…Vollenweider et al., 1998), imaging (Carhart-Harris, Erritzoe, et al., 2012a; Carhart-Harris, Leech, et al., 2012b; Carhart-Harris et al., 2013) and small pilot clinical studies (Bogenschutz et al., 2015; Carhart-Harris et al., 2016; Grob et al., 2011; Johnson et al., 2014; Moreno et al., 2006).”
BackgroundAsymmetry in Psychoactive Research: A Bibliometric Study on 15 Psychoactive Drugs
Lebrero-Tatay, J., Sebag, A., & Ezquerra-Romano, I. (2022) · Journal of Drug Issues · doi:10.1177/00220426211068439 · Cited by 18
“During the late 1980s, despite the rise of recreational use and general decline in psychedelic research (Lawrence et al., 2021), the Swiss Federal Office for Public Health granted special permission psychiatry and psychotherapy specialists to use psilocybin and LSD.”
BackgroundPsychedelics and Evidence-based Psychotherapy
Leone, L., McSpadden, B., DeMarco, A., Enten, L., Kline, R., & Fonzo, G. A. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.02.006 · Cited by 18
Psychedelic risks and benefits: A cross-sectional survey study
Goldy, S. P., Du, B. A., Rohde, J. S., Nayak, S. M., Strickland, J. C., Ehrenkranz, R. C., Levine, M., Barrett, F. S., & Yaden, D. B. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241292951 · Cited by 18
“…Davis et al., 2021; D’Souza et al., 2022; Goodwin et al., 2023; Raison et al., 2023), end-of-life anxiety and depression (Griffiths et al., 2016; Grob et al., 2011; Muttoni et al., 2019; Ross et al., 2016), and substance use disorder (Bogenschutz et al., 2015, 2022; Johnson et al., 2014, 2017).”
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review
Meshkat, S., Malik, G., Zeifman, R. J., Swainson, J., Balachandra, K., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106163 · Cited by 21
Hutchison, K. E., Hooper, J. F., & Karoly, H. C. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3038 · Cited by 21
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Lee, Y. K., Gold, M. S., & Fuehrlein, B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120094 · Cited by 20
Barrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022) · Frontiers in Neuroergonomics · doi:10.3389/fnrgo.2021.784576 · Cited by 20
Self-citationAssociation between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample
Mellner, C., Dahlén, M., & Simonsson, O. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811353 · Cited by 18
Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111753 · Cited by 18
Hogea, L., Tabugan, D. C., Costea, I., Albai, O., Nussbaum, L. A., Cojocaru, A., Corsaro, L., & Anghel, T. (2025) · Medicina · doi:10.3390/medicina61020278 · Cited by 19
It’s time to take psilocybin seriously as a possible treatment for substance use disorders
Bogenschutz, M. P. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1200060 · Cited by 18
“low-up, based on the self-report validated by urinary cotinine and breath carbon monoxide levels (2).”
MethodScheidegger, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_3 · Cited by 21
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123424 · Cited by 16
Validation of the imperial psychedelic predictor scale
Angyus, M., Osborn, S., Haijen, E. C. H. M., Erritzøe, D., Peill, J. M., Lyons, T., Kettner, H., & Carhart-Harris, R. L. (2024) · Psychological Medicine · doi:10.1017/s0033291724002204 · Cited by 20
Kittur, M. E., M, L. A. B., Jones, B. D. M., Blumberger, D. M., Mulsant, B. H., Rosenblat, J. D., & Husain, M. I. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119952 · Cited by 19
Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward
Jaster, A. M., Hadlock, T. M., Buzzi, B., Maltman, J. L., Silva, G. M., Saha, S., Köşeli, E., Pondelick, A. M., Thakur, N., Zhang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64887-w · Cited by 19
Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey
Roméo, B., Fauvel, B., Dejean, S., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2227171 · Cited by 17
“Studies have been conducted in the field of treatment-resistant depression (Carhart-Harris et al. 2016, 2021; Palhano-Fontes et al. 2019), but also of addiction, such as tobacco (Johnson et al. 2014; Johnson, Garcia-Romeu, and Griffiths 2017) or alcohol use disorder (Bogenschutz et al. 2015, 2022).”
BackgroundResultGlynos, N. G., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1349565 · Cited by 17
Gomez-Escolar, A., Folch‐Sanchez, D., Stefaniuk, J., Swithenbank, Z., Nisa, A., Braddick, F., Chaudhary, N. I., van der Meer, P. B., & Batalla, A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01101-3 · Cited by 21
“In addition to treatment-resistant depression, the efficacy of psychedelics such as psilocybin have been assessed for SUDs with promising results [19, 20].”
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 18
“A wealth of studies has since shown the remarkable therapeutic potential of these drugs for the treatment of several disorders, including treatment-resistant depression [26], anxiety [67,77], obsessive-compulsive disorder (OCD) [132] and addiction [17, 91].”
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
Zeiss, R., Gahr, M., & Graf, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100985 · Cited by 20
“, tobacco addiction [26], alcohol dependence [27], anxiety in cancer patients [28,29], obsessive compulsive disorder [30], and depression [31].”
BackgroundDaldegan‐Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., & Maia, L. O. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2063896 · Cited by 20
“There is a growing body of evidence for psychedelics as a potential tool to assist addiction treatment, including alcohol and tobacco (Johnson et al., 2014; Krebs & Johansen, 2012; Sessa & Johnson, 2015).”
BackgroundEffects of LSD on music-evoked brain activityPreprint
Kaelen, M., Lorenz, R., Barrett, F. S., Roseman, L., Orbán, C., Santos-Ribeiro, A., Wall, M. B., Feilding, A., Nutt, D. J., Muthukumaraswamy, S. D., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/153031 · Cited by 19
“…effects within “psychedelic therapy” - a therapeutic approach that is characterised by lengthy periods of introspective music-listening during drug effects (Carhart-Harris et al., 2016b; Gasser et al., 2014; Griffiths et al., 2016; Grob CS et al., 2011; Johnson et al., 2014; Ross et al., 2016).”
BackgroundA systematic review of income and education reporting in psychedelic clinical trials
Grossman, D. H., Madden, K. R., Mehtani, N. J., Anderson, B. T., Davis, L. L., Mitchell, J., & Hendricks, P. S. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00417-3 · Cited by 17
Benvenuti, F., Colombo, D., Soverchia, L., Cannella, N., Domi, E., & Ciccocioppo, R. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06384-w · Cited by 18
“More important initial clinical findings suggest that psilocybin might be a valuable compound for the treatment of various form of addictions including alcoholism (Bogenschutz 2013; Bogenschutz et al. 2015; De Veen et al. 2017; Johnson et al. 2014).”
BackgroundPsilocybin: From Psychiatric Pariah to Perceived Panacea
Fonzo, G. A., Wolfgang, A. S., Barksdale, B. R., Krystal, J. H., Carpenter, L. L., Kraguljac, N. V., Grzenda, A. L., McDonald, W. M., Widge, A. S., Rodríguez, C. I., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230682 · Cited by 20
Ayahuasca: what mental health professionals need to know
dos Santos, R. D., Bouso, J., & Hallak, J. (2017) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000130 · Cited by 12
Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
“In addition to healthy volunteers, this profile is also seen in patients with a variety of Diagnostic and Statistical Manual of Mental Disorders categories, such as cancer-related anxiety, SUD, and major depressive disorder [54, 64, 67, 69].”
Analytical characterization of seventeen ring-substituted N,N-diallyltryptamines
Brandt, S. D., Kavanagh, P., Dowling, G., Talbot, B., Westphal, F., Meyer, M., Maurer, H., & Halberstadt, A. (2016) · Drug Testing and Analysis · doi:10.1002/dta.1974 · Cited by 13
“have also been the focus of attention due to increasing research efforts in clinically important areas [6-10] including potential treatment options for cluster headaches.”
Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. E. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00249-z · Cited by 19
Weiss, B., Sleep, C., Miller, J. D., & Campbell, W. K. (2023) · Journal of Personality Disorders · doi:10.1521/pedi.2023.37.2.131 · Cited by 15
What is Psychological Support in the Context of Psychedelic Clinical Trials?
Richard, J., & Levine, M. A. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0026 · Cited by 14
“10,30,31 Should psychedelic treatments be approved for use outside of clinical trials, practitioners will likely have more leeway to adopt eclectic or integrative psychotherapeutic approaches.”
Berkovitch, L., Fauvel, B., Preller, K. H., & Gaillard, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106239 · Cited by 16
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001724 · Cited by 16
Kinderlehrer, D. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s500337 · Cited by 15
Murnane, K. S., Güner, O. F., Bowen, J. P., Rambacher, K. M., Moniri, N. H., Murphy, T. J., Daphney, C. M., Oppong‐Damoah, A., & Rice, K. C. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.003 · Cited by 16
A dangerous method? Psychedelic therapy at Modum Bad, Norway, 1961–76
Johnstad, P. G. (2020) · History of Psychiatry · doi:10.1177/0957154x19894537 · Cited by 15
Effectiveness of Psilocybin on Depression: A Qualitative Study
Alshaikhli, H., Al-Naggar, R. A., & Erlam, G. D. (2021) · Electronic Journal of General Medicine · doi:10.29333/ejgm/10862 · Cited by 21
“The positive effects of this drug are well documented as shown by the fact that 80 percent of long-term heavy cigarette smokers demonstrated abstinence from smoking six months following two psilocybin therapy sessions [14].”
BackgroundInfluentialNew Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders
Dakwar, E., & Nunes, E. V. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0703-4 · Cited by 15
Psychedelic drugs in the treatment of anxiety, depression and addiction
Kvam, T.-M., Stewart, L. H., & Andreassen, O. A. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.1110 · Cited by 15
Postpartum depression: A role for psychedelics?
Jairaj, C., & Rucker, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221093793 · Cited by 16
“…of psilocybin given with psychological support in the treatment of depression (Carhart-Harris et al., 2016; Davis et al., 2021), end-of-life distress (Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), and substance use disorders (Bogenschutz et al., 2015; Johnson et al., 2014).”
BackgroundBibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies
Weleff, J., Akiki, T. J., & Barnett, B. S. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2133757 · Cited by 14
“The first of these is a transition from research focused on potential risks of psychedelics (MDMA in particular) towards research into their therapeutic potential, with nine of the papers focused on therapeutic applications of LSD, MDMA and psilocybin (Grob et al. 2011; Roland R Griffiths et al. 2016; R. L. Carhart-Ha…”
BackgroundThe association between naturalistic use of psychedelics and co-occurring substance use disorders
Rabinowitz, J., Lev‐Ran, S., & Gross, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1066369 · Cited by 15
Wang, K., Sun, Y., Nava, B., Sampiere, L., & Jacobs, R. J. (2023) · Cureus · doi:10.7759/cureus.37450 · Cited by 14
Holikulov, U., Kazachenko, А. S., Issaoui, N., Казаченко, А. С., Raja, M., Al-Dossary, O. M., & Xiang, Z. (2024) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2024.124600 · Cited by 14
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
Vamvakopoulou, I. A., & Nutt, D. J. (2024) · European Addiction Research · doi:10.1159/000540062 · Cited by 18
“Johnson et al. [51] and Garcia-Romeu et al. with a similar concept approached tobacco use disorder with two psilocybin doses plus a combination of cognitive behavioural therapy and mindfulness training for smoking cessation.”
Larsen, K., Lindberg, U., Ozenne, B., McCulloch, D. E.-W., Armand, S., Madsen, M. K., Johansen, A., Stenbæk, D. S., Knudsen, G. M., & Fisher, P. M. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251323364 · Cited by 14
Psilocybin for depression: Considerations for clinical trial design
O’Donnell, K. C., Mennenga, S. E., & Bogenschutz, M. P. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.026 · Cited by 18
Psilocybin and palliative end-of-life care
Shelton, R. C., & Hendricks, P. S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675764 · Cited by 14
Stewart, B., Dean, J. G., Koek, A. Y., Chua, J. P., Wabl, R., Martin, K., Davoodian, N., Becker, C. J., Himedan, M., Kim, A., et al. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.688 · Cited by 14
Global Drug SurveyPreprint
Petranker, R., Anderson, T., Maier, L. J., Barratt, M. J., Ferris, J., & WINSTOCK, A. R. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/xb8ve · Cited by 14
Borgland, S. L., & Neyens, D. M. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.220090 · Cited by 14
Psilocybin or Nicotine Patch for Smoking Cessation
Johnson, M. W., Naudé, G. P., Hendricks, P. S., & Garcia‐Romeu, A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0972 · Cited by 14
Self-citationEntheogenic Spirituality: Characteristics of Spiritually Motivated Psychedelics Use
Johnstad, P. G. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148060 · Cited by 15
“…et al., 2021; Griffiths et al., 2016; Roseman et al., 2018; Ross et al., 2016), anxiety (Gasser et al., 2013; Goldberg et al., 2020; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), and substance dependence (Bogenschutz et al., 2015; Garcia-Romeu et al., 2019; Johnson et al., 2014).”
BackgroundA Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe
Serreau, R., Amirouche, A., Benyamina, A., & Berteina‐Raboin, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010040 · Cited by 13
“They have also been suggested more recently as a treatment for behavioral disorders and alcohol [36] or tobacco addiction [32,37,38].”
BackgroundInteractive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers
Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Oña, G., Silveira, G. D. O., Yonamine, M., Bertozi, G., Crevelin, E. J., Queiroz, M. E. C., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001691 · Cited by 14
Manic episode following psilocybin use in a man with bipolar II disorder: a case report
Halim, H. J., Burk, B. G., Fargason, R. E., & Birur, B. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1221131 · Cited by 13
“Several studies have been published highlighting the use of psilocybin use for the treatment of obsessive-compulsive disorder, treatment-resistant depression, and some substance use disorders (10, 14–16).”
Pouyan, N., Sisi, F. Y., Kargar, A., Scheidegger, M., McIntyre, R. S., & Morrow, J. D. (2023) · CNS Drugs · doi:10.1007/s40263-023-01044-1 · Cited by 13
“In support of this concept, recent human clinical trials have indicated that the classical hallucinogen psilocybin shows promise as a treatment for tobacco and alcohol use disorders when administered alongside concurrent psychotherapy [15, 137, 138].”
BackgroundAtiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 16
“Johnson et al. carried out an open-label pilot study to assess the safety and feasibility of psilocybin-facilitated smoking cessation treatment (Johnson et al. 2014).”
Nicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 13
Rose, J. R. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00363 · Cited by 17
Elfrink, S., & Bergin, L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1528253 · Cited by 16
Four individuals' experiences during and following a psilocybin truffle retreat in the Netherlands
Lutkajtis, A. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00162 · Cited by 15
Mohamed, A., Touheed, S., Ahmed, M., Hor, M., & Fatima, S. (2022) · Cureus · doi:10.7759/cureus.30919 · Cited by 17
Psychedelic Psychodynamics: Relational Knowing and the Unthought Known
Barrett, K. (2022) · Psychoanalytic Dialogues · doi:10.1080/10481885.2022.2106141 · Cited by 15
“Pilot studies have shown promising results in treating alcohol and nicotine dependence (Bogenschutz et al., 2015; Johnson et al., 2014) and treatment-resistant depression (CarhartHarris et al., 2018).”
BackgroundYaden, D. B., Berghella, A. P., Hendricks, P. S., Yaden, M. E., Levine, M., Rohde, J. S., Nayak, S. M., Johnson, M. W., & Garcia‐Romeu, A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106998 · Cited by 13
Self-citationNeurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets
Tylš, F., Páleníček, T., & Horáček, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00073-x · Cited by 14
A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents
Bogadi, M., & Kaštelan, S. (2021) · Croatian Medical Journal · doi:10.3325/cmj.2021.62.528 · Cited by 13
Human behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
Self-citationCarlisle, N. A., Dourron, H. M., MacCarthy, S., Zarrabi, A. J., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0018 · Cited by 15
“3,33 Additional research is needed to understand if and how these effects may be different for SGM populations, with attention to differences by sub-group (e.g., gay men compared with lesbian women) and other core identities (e.g., race and ethnicity).”
Breau, J. A., & Gillis‐Smith, P. (2023) · Interdisciplinary Science Reviews · doi:10.1080/03080188.2023.2266322 · Cited by 16
“…as treatments for alcoholism (Bogenschutz et al. 2022), depression (Carhart-Harris et al. 2021; Palhano-Fontes et al. 2019), tobacco addiction (Johnson et al. 2014), and other mental health conditions (Gri ffi ths et al. 2016; Ross et al. 2016), researchers have become invested in ‘ mystical…”
BackgroundSpending Time in Nature: The Overlooked Health Behavior
Maddock, J. E., & Johnson, S. S. (2023) · American Journal of Health Promotion · doi:10.1177/08901171231210806 · Cited by 16
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001727 · Cited by 13
“29 Psilocybin also reduced heavy drinking days by 13.9% relative to placebo in an RCT with 93 participants.”
BackgroundInfluentialSakai, K., Bradley, E., Zamaria, J. A., Agin-Liebes, G., Kelley, D. P., Fish, A., Martini, V., Ferris, M. C., Morton, E. E., Michalak, E. E., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06585-x · Cited by 15
“…including depressive and anxiety disorders (Anderson et al. 2020; Carhart-Harris et al. 2016; Davis et al. 2020; Griffiths et al. 2016; Moreno et al. 2006), headache disorders (Schindler 2022; Schindler et al. 2021), and substance use disorders (Bogenschutz et al. 2015; Johnson et al. 2014).”
Less is more? A review of psilocybin microdosing
Savides, I. A., & Outhoff, K. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278769 · Cited by 14
“…TRD as well as obsessive-compulsive disorder (OCD) and substance use disorders including nicotine and alcohol (Bogenschutz et al., 2022; Carhart-Harris et al., 2016, 2021; Goodwin et al., 2023; Grob et al., 2011; Johnson et al., 2014; Kelmendi et al., 2022; Raison et al., 2023; Yu et al., 2021).”
Psychedelics as a potential treatment for tobacco use disorder: a systematic review
Spoelstra, S. K., Schoevers, R. A., Venema, S. D., & Knegtering, H. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00095-0 · Cited by 12
“Among the 8 publications reviewed, psychedelic treatment was combined with cognitive-behavioral therapy in 4 publications (Johnson et al. 2014 and its follow-ups).”
BackgroundInfluentialJones, G. M., Lowe, M. X., Nayak, S. M., Sepeda, N. D., Kettner, H., Carhart-Harris, R. L., Jackson, H., & Garcia‐Romeu, A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.058 · Cited by 12
Self-citation
Metadata
- Authors
- Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2014-09-11
- Volume
- 28
- Issue
- 11
- Pages
- 983-992
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC4286320
- OpenAlex
- W2122459973
- Cited by
- 914
- References
- 63
- Citations by year
- 2026: 71 · 2025: 130 · 2024: 126 · 2023: 112 · 2022: 121 · 2021: 94 · 2020: 70 · 2019: 33 · 2018: 48 · 2017: 45 · 2016: 46 · 2015: 13 · 2014: 3
- FWCI
- 41.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- World Health Organization
- National Institute on Drug Abuse (R01DA003889, T32DA007209)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psilocybin, tobacco dependence, smoking cessation, nicotine dependence, hallucinogens, 5-HT2A receptor agonists, adjunctive therapy, abstinence, treatment safety and feasibility
- MeSH terms
- Attitude, Carbon Monoxide, Combined Modality Therapy, Cotinine, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Tobacco Use Disorder, Biomarkers, Cognitive Behavioral Therapy, Smoking Cessation, Behavior, Addictive, Treatment Outcome, Serotonin Receptor Agonists, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
